Martin Simonetti work email
- Valid
- Valid
- Valid
- Valid
- Valid
Martin Simonetti personal email
- Valid
Martin Simonetti phone numbers
-C-level executive (CEO, CFO); managed growth in organizations ranging from private pre-commercial to world class Fortune 500-Led successful financing via both private and public capital markets (venture, IPO, secondary offerings, etc)-Successfully executed multiple large pharma collaborations-Public and private company Board of Directors experience-Qualified Audit Committee Director, meet SEC requirement for "financial expert"I served as VLST's President and Chief Executive Officer from 2005 to 2013. From 1999 to 2005, I was employed at Dendreon Corporation, most recently serving as the Chief Financial Officer, Senior Vice President Finance and Treasurer. From 1991 to 1998, I was employed at Amgen Inc., serving as the Vice President Operations and Finance of Amgen BioPharma and its Director of Colorado Operations. From 1984 to 1991, I worked at Genentech, Inc., first as a scientist in its Medicinal and Analytical Chemistry Department and later as a financial analyst and group controller. I served on the boards of directors of Alexandria Real Estate Equities (NYSE: ARE), based in Pasadena, California from 2005 - 2013 and Icagen, Inc., a Nasdaq company, from 2005 until its sale to Pfizer in 2011. I am a member of the board of directors of Curtana. I received an M.S. from the University of California, Davis and an M.B.A. from the University of Santa Clara.
-
Managing PartnerMasx2 Partners LlcScottsdale, Az, Us
-
Board Of DirectorsCurtana Pharmaceuticals Aug 2015 - PresentAustin, Texas AreaCurtana Pharmaceuticals, founded in 2013, is a privately held, preclinical-stage biopharmaceutical company headquartered in Austin, Texas. In August 2014, the company was awarded a $7.6 million grant from the Cancer Prevention and Research Institute of Texas. Curtana focuses on the development of novel first-in-class, small molecule therapeutics targeting cancer stem cells in the central nervous system for the treatment of glioblastoma and other cancers. Curtana’s OLIG2 inhibitors will be the only adjuvant treatment for nearly all gliomas, including high-grade glioblastomas, which specifically targets the cancer stem cells and is a potent radiosensitizer.
-
Managing PartnerMasx2 Partners Llc Mar 2014 - PresentI provide a combination of business development and financial strategy, as well as general management support to emerging, mid-size and large biotechnology companies. I am available to sit on boards based on prior experience on both Nasdaq and NYSE listed companies. I am a qualified financial expert and can serve on audit, N&G and compensation committees. My background includes taking a company public, raising over $500M privately and publicly, successful M&A transactions and completing multiple large pharma collaboration deals.
-
Board Of DirectorsLanier Biotherapeutics Jul 2021 - Jun 2023Bogart, Georgia, United StatesLanier discovers and develops antibody treatments to restore and improve better health: seeing, breathing, and believing.RetinalBiobetter multifunctional anti-VEGF antibodies.Type 2 InflammationModerate-to-severe conditions, like asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis and food allergies, with limited response to corticosteroid treatment.Immuno-OncologyProprietary antibody offerings.MT-6402 in the clinic with Molecular Templates. -
Board Of DirectorsAbeome Corporation Apr 2018 - Jun 2023Athens, Georgia, United StatesAbeome's DiSH technology is the key to driving unprecedented efficiencies in screening for new targets. Using DiSH, desired monoclonals can be identified using fluorescent-labeled antigens to bind surface-expressed antibodies, making isolation and cloning desired cells significantly easier. Abeome is actively looking for partners interested in leveraging the company’s DiSH technology to enable accelerated pre-clinical identification and screening of monoclonal antibody targets. Our strategy encompasses licensing the platform technology to leading pharmaceutical/biotech companies, offering fee-for-service antibody generation, and co-developing our own mAbs for key therapeutic and diagnostic applications. Non-exclusive licenses are available for unlimited access and commercialization of the technology, or by specific fields of interest (i.e., research use only, diagnostics, animal health). -
Board Of DirectorsEpithany Jan 2015 - Mar 2021Seattle, WaEpiThany, Inc.TM was founded in 2014 in Seattle to consolidate the discovery technology and clinical stage assets of the Tumor Vaccine Group (TVG) and the pioneering work of Dr. Nora Disis. Since identifying the HER-2 tumor antigen in breast cancer in the early 1990’s, Dr. Disis and the TVG have taken their laboratory discoveries into early clinical development. The products under development are multi-epitope DNA vaccines that target multiple antigens overexpressed in cancer for the treatment and prevention of solid tumors. These vaccines are engineered to selectively stimulate inflammatory (Th1) immunity to tumor antigens, without producing the tolerogenic (Th2) immune response that typically arises from self-antigens.The current portfolio of patents licensed from the University of Washington includes two clinical-stage programs, one clinic- ready program in addition to a library of well characterized antigens and epitopes geared toward generating Th1 specific immunity against a variety of human cancers while avoiding stimulating a competitive Th2 response. Delivery of these therapeutics via a straightforward plasmid DNA vector makes them simple to manufacture, store, transport, and administer. Clinical trials have shown them to be well-tolerated with desirable immunogenicity characteristics.
-
Board Of DirectorsVlst Corp Nov 2005 - Dec 2020 -
President & CeoVlst Corporation Nov 2005 - Apr 2013Greater Seattle Area
-
Chairman Board Of DirectorsNexgenia Oct 2014 - Jun 2019Greater Seattle AreaNexgenia develops and manufactures proprietary polymers and polymer-containing magnetic nanoparticles. These unique polymers change state – from soluble single molecules to large macromolecular aggregates – in response to very modest changes of temperature, pH, or salt in their environment. When these polymers are attached to other chemicals / biologicals, they confer the same environmentally-responsive characteristics. Thus the resulting combinations can be small when it is advantageous to be small and large when that facilitates separation and analysis. This property enables the development of faster, more complete molecular / cellular separations and faster, more sensitive immunoassays.The emerging field of personalized immunotherapies, such as CAR T-cell therapies, rely heavily on the ability to separate cells from a patient sample quickly and efficiently. Nexgenia’s polymer-bearing nanoparticles enable antibodies to be utilized at much higher concentrations and to bind with targets much faster. Following target binding, the nanoparticles can be converted within seconds to large size for faster more complete separations leading to faster and more sensitive assays.
-
Chair Of The Board Of DirectorsLife Science Washington Jan 2017 - Dec 2017Greater Seattle Area -
Executive Committee - Board Of DirectorsLife Science Washington Jan 2010 - Dec 2016Greater Seattle Area
-
Member Board Of DirectorsPrismic Pharmaceuticals, Inc. Jul 2015 - Dec 2016Scottsdale, AzPrismic Pharmaceuticals, Inc. is a privately held specialty pharmaceutical company developing highly differentiated proprietary products in two distinct FDA categories, Prescription Drugs and Prescription Medical Foods, based on its two lead pharmaceutically active ingredients, ultra-micronized palmitoylethanolamide, and ultra-pure, high EPA, Omega-3. The company is developing products to address three key therapeutic areas with very large patient populations, and where there are clear and significant unmet clinical needs, namely, chronic kidney disease, depression, and severe chronic pain. -
Board Of DirectorsAlexandria Real Estate Equities, Inc. Dec 2005 - May 2013Pasadena, Ca -
Board Of DirectorsIcagen Jun 2005 - Oct 2011North Carolina
-
Cfo, Svp Finance & TreasurerDendreon Dec 1998 - Jul 2005Greater Seattle Area -
Vp Finance & OpsAmgen Aug 1991 - Apr 1998Thousand Oaks, Ca -
Group ControllerGenentech Dec 1983 - Aug 1991South San Francisco, Ca -
Research AssociatePeninsula Laboratories Oct 1980 - Dec 1983San Carlos, Ca
Martin Simonetti Skills
Martin Simonetti Education Details
-
Finance -
Nutritional Sciences -
Nutritional Sciences
-
Associate Of Science (A.S.)
Frequently Asked Questions about Martin Simonetti
What company does Martin Simonetti work for?
Martin Simonetti works for Masx2 Partners Llc
What is Martin Simonetti's role at the current company?
Martin Simonetti's current role is Managing Partner.
What is Martin Simonetti's email address?
Martin Simonetti's email address is ms****@****eon.com
What is Martin Simonetti's direct phone number?
Martin Simonetti's direct phone number is (206) 262*****
What schools did Martin Simonetti attend?
Martin Simonetti attended Santa Clara University, University Of California, Davis, University Of California, Davis, College Of San Mateo.
What skills is Martin Simonetti known for?
Martin Simonetti has skills like Biotechnology, Biopharmaceuticals, Pharmaceutical Industry, Lifesciences, Commercialization, Clinical Development, Clinical Trials, Mergers And Acquisitions, Technology Transfer, Drug Discovery, Oncology, Fda.
Who are Martin Simonetti's colleagues?
Martin Simonetti's colleagues are Ramya B, Adam Saunders, Oluwaseun Faluyi.
Not the Martin Simonetti you were looking for?
-
1email.de -
-
-
Martín Simonetti
Portfolio Solutions I Investment Advisory I Wealth ManagementSantiago Metropolitan Area1principal.com
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial